The Definition of Meritorious
Martine Elias, Executive Director
"On that day, Aldo was being recognized and honoured for the impact he’s had on the myeloma community by creating Myeloma Canada, the only grassroots Canadian organization exclusively focused on making myeloma matter through community empowerment, education, awareness, advocacy and research. I could not have been prouder of our co-founder and my dear friend." 
The results are in for the
2018 Multiple Myeloma March!
We are very pleased to announce that the 2018 Multiple Myeloma March
raised $580 495 so far!

Not only have we exceeded our objective, but we are very close to $600,000. This is a wonderful way to mark the 10th anniversary of the signature Myeloma Canada event aimed at increasing awareness, raising funds for clinical research, and supporting advocacy for access to new therapies.

We would like to thank all 23 communities across the country who took part in the Multiple Myeloma March this year; we could not have done it without you. Whether you were a participant, organizer, volunteer or donor, you were an integral part of the overall success.

Thank you for celebrating 10 years with us!

If you didn’t get a chance to support the March in your community, but would like to contribute, the website will stay open until the end of the year.
Your opinion counts! In the next few weeks, we will be emailing out a 2018 Multiple Myeloma March experience survey. Your feedback is greatly appreciated. Stay tuned!
Research Updates
Kyprolis is Now Covered in Alberta 
We are pleased to announce the Alberta Health Services has listed Kyprolis in combination with Revlimid (lenalidomide) and dexamethasone or with dexamethasone alone, for patients with multiple myeloma who have received one to three prior lines of treatment.
Find Clinical Trials
We invite you to try Myeloma Canada’s clinical trial personalized search tool! This simplified user-friendly tool allows you to receive email alerts on upcoming trials based on the stage of your disease, your place of residence and the clinical trial phase you are interested in. 
Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
On October 29, 2018, Genmab A/S (Nasdaq Copenhagen: GEN) announced topline results from the Phase III MAIA study (MMY3008) of daratumumab in combination with lenalidomide and dexamethasone (DRd) versus Rd alone as treatment for newly diagnosed patients who are not candidates for high dose chemotherapy and autologous stem cell transplant (ASCT). The study met the primary endpoint of improving progression free survival (PFS) at a pre-planned interim analysis resulting in a 45% reduction in the risk of progression or death in patients treated with DRd. 
Taking Action
  • Myeloma Canada descends on Queen’s Park in Toronto with our message to make myeloma matter!

  • Myeloma Canada Presents at the Oncology Drug Navigators of Ontario (ODANO) Conference

  • Myeloma Canada at the 30th Annual CANO/ACIO Conference
Spotlight on Wanda Joyce McLean:
Undergoing an Umbilical Cord Stem Cell Transplant
"Life isn’t always fair and sometimes it throws us a curve ball that we aren’t prepared for. I’m too young to die from this disease! We need to invest in the younger cancer patients as well, they have a whole life ahead and their number is growing."
Upcoming Events
Grande Prairie InfoSession

November 24, 2018
Pomeroy Hotel & Conference Centre
Grande Prairie, Alberta

For patients, caregivers, healthcare professionals and the myeloma community.
Myeloma Canada National Conference
Save the date!
April 27-28, 2019
Radisson Admiral Hotel – Toronto Harbourfront
Toronto (Ontario)
In the community
  • Myeloma Canada Holds the First-ever InfoSession for Healthcare Professionals in Whitehorse

  • The 3rd Annual Sam's Monte Carlo Casino Night raised $48,500!

  • The Myeloma Canada Support Group Leader Summit